Published date: 17 January 2022

Awarded contract - This means that the contract has been awarded to a supplier.


Closing: 19 December 2021, 11pm

Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

SW1H 0EU

Value of contract

£1

Procurement reference

CF-0581300D0O000000rwimUAA1

Published date

17 January 2022

Closing date

19 December 2021

Closing time

11pm

Contract start date

20 December 2021

Contract end date

31 December 2022

Contract type

Supply contract

Procedure type

Negotiated procedure without prior publication (above threshold)

The opportunity was not advertised, because for example only one supplier is capable of delivering the requirement, or due to extreme urgency brought about by unforeseen events.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative.
This agreement is for the procurement of 1,750,000 units of Molnupiravir (EIDD-2801/MK-4482). It is one of the first oral and direct-acting antiviral drugs globally and the first to receive regulatory approval and is part of the UK's multi-layered approach to COVID-19.

More information

Links

Award information

Awarded date

20 December 2021

Contract start date

20 December 2021

Contract end date

31 December 2022

Total value of contract

£1

This contract was awarded to 1 supplier.

Merck Sharpe & Dohme (UK) Limited

Address

120 Moorgate EC2M 6UR

Reference

None

Supplier is SME?

No

Supplier is VCSE?

No

About the buyer

Contact name

Amy Watkins

Address

39 Victoria Street
London
SW1H 0EU
GB

Email

AntiviralsTaskforce@dhsc.gov.uk